{"analyses":[{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.30","estimateComment":"Reference level = TAS x 8 weeks","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.62","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"12","value":"10"},{"groupId":"OG001","lowerLimit":"7","upperLimit":"12","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"737"}],"units":"Participants"}],"description":"Time to SBF measured from date of randomization to the date of PSA increase of ≥1.0 ng/mL (from the nadir PSA after completion of protocol-specified therapy) after salvage androgen suppression was started; competing risks LRP, DM, and death without SBF; all others are censored. SBF is estimated using the cumulative incidence method. Ten-year rates are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG000","title":"TAS x 8 Weeks"},{"description":"TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG001","title":"TAS x 28 Weeks"}],"paramType":"NUMBER","populationDescription":"Eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)","title":"Time to Second Biochemical Failure (SBF) (10-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}